Malignant hyperthermia: Diagnosis and management of acute crisis An MH event does not necessarily occur every time an MH susceptible individual is exposed to an anesthetic triggering agent [7] Approximately one-half of patients who develop acute MH have had one or two uneventful exposures to triggering agents [8,9]
Malignant hyperthermia susceptibility: Evaluation and management Patients who are susceptible to MH have skeletal muscle excitation-contraction receptor or adaptor protein (eg, STAC3) abnormalities that allow excessive myoplasmic calcium to accumulate in the presence of the anesthetic triggering agents
Susceptibility to malignant hyperthermia: Evaluation and . . . - UpToDate Patients who are susceptible to MH have skeletal muscle receptor abnormalities that allow excessive myoplasmic calcium to accumulate in the presence of the aforementioned anesthetic triggering agents Very little is known about the specific mechanisms by which anesthetics interact with these abnormal receptors to trigger an MH crisis [4-6]
Malignant hyperthermia rapid overview - UpToDate Malignant hyperthermia rapid overview of emergency management For further information, refer to UpToDate content on management of an acute MH crisis
Medline ® Abstracts for References 7,67 of Malignant . . . - UpToDate BACKGROUND Malignant hyperthermia (MH) susceptibility is a heritable musculoskeletal disorder that can present as a potentially fatal hypermetabolic response to triggering anesthesia agents Genomic screening for variants in MH-associated genes RYR1 and CACNA1S provides an opportunity to prevent morbidity and mortality
Neuroleptic malignant syndrome - UpToDate Neuroleptic malignant syndrome (NMS) is a neurologic emergency associated with the use of antipsychotic (neuroleptic) agents and characterized by a distinctive clinical syndrome of mental status change, rigidity, hyperthermia, and dysautonomia [1]
Error - UpToDate Trusted medical resource offering evidence-based clinical information for healthcare professionals